Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Instrumentation
Carlyle Group takes a major stake in Unchained Labs
by Rick Mullin
April 30, 2021
| A version of this story appeared in
Volume 99, Issue 16
The Carlyle Group has agreed to acquire a majority stake in Unchained Labs, a life sciences instrumentation company focused on biologics and gene therapy research, for $435 million. Unchained, which supplies tools for analyzing and characterizing complex large molecules, has 170 employees and expects to generate over $75 million in revenue this year. Its products include Uncle, a protein analysis instrument for gene therapy research that combines fluorescence, static light scattering, and dynamic light scattering measurement modes.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter